Corcept Therapeutics Incorporated

NASDAQ:CORT

Biotechnology

Healthcare
$67.79 -2.34%

-$1.96 today

Market cap
$7.42B
Beta
0.50
P/E (TTM)
178.2
EPS (TTM)
$0.46
52W Low $28.66High $91.00

Volume 0.74M

Average 1.41M

CORT Sales of Investments

Cash received from selling or redeeming investments.

Corcept Therapeutics IncorporatedNASDAQ: CORT

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments declines year over year

Q2 FY2026 sales of investments of $62.24M fell 33.4% year over year, ahead of the -35.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 9.1% from the prior quarter. Over 3 fiscal years it compounded at +17.3% a year.

Context

  • Sales of investments amounted to 51.2% of revenue in FY2025, down 10.0 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -33.4% holds above the trailing-twelve-month pace of -35.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$62.24M+9.1% QoQ
Last fiscal yearDec 2025
$389.58M-5.6% YoY
LTMJun 2026
$303.35M-35.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.4%——
1 year-5.6%——
3-year CAGR+17.3%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
389.58M USD
Year-over-year change
-5.6%
4-year CAGR
-3.5%

Sales of Investments vs competitors

How CORT compares with its peers on the latest reported figures

  • CORT's LTM Jun 2026 sales of investments of $303.35M is the largest of the 3 companies compared; the peer median is $145.75M.
  • Its year-over-year change of -35.0% is the lowest of 2, against a peer median of +36.0%.
  • Sales of investments amounts to 36.5% of revenue for CORT.
CORT Competitors Peer median
Sales of Investments for CORT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$303.35M -35.0%+17.3%36.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$291.5M +36.0%+207.1%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 ———
Peer median (excluding CORT) $145.75M+36.0%+207.1%—

Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income112.51M101.42M106.14M141.21M98.17M
Depreciation & Amortization3.07M3.45M2.36M1.34M1.89M
Deferred Income Tax4.35M(33.91M)(29.49M)(40.19M)0
Stock-Based Compensation42.93M42.44M48.94M61.35M84.5M
Change in Working Capital(57K)5.54M8.22M45.3M(27.57M)
Accounts Receivables(1.43M)(17.43M)(10.07M)1.15M(5.81M)
Inventory3.44M1.2M1.27M305K(7.48M)
Accounts Payables(3.6M)4.76M5.78M(2.25M)25.07M
Other Working Capital1.52M17.02M11.24M46.09M(39.34M)
Other Non-Cash Items5.09M1.38M(9.13M)(10.94M)(15M)
Operating Cash Flow167.89M120.32M127.04M198.07M142M
Capital Expenditures(469K)(413K)(139K)(2.17M)(211K)
Acquisitions (Net)(136.6M)0000
Purchases of Investments(312.81M)(355.07M)(328.75M)(588.31M)(319.61M)
Sales of Investments449.4M241.15M419.79M412.88M389.58M
Other Investing Activities136.6M0000
Investing Cash Flow136.13M(114.33M)90.91M(177.6M)69.76M
Debt Repayment00000
Common Stock Issued0009.62M0
Common Stock Repurchased(295.99M)0(145.43M)(15.66M)(245.86M)
Dividends Paid00000
Other Financing Activities(6.61M)(17.28M)(3.3M)(22.3M)25.49M
Financing Cash Flow(302.59M)(17.28M)(148.72M)(28.35M)(220.37M)
Effect of Forex Changes00001.44M
Net Change in Cash1.43M(11.29M)69.22M(7.89M)(7.17M)
Free Cash Flow167.42M119.91M126.9M195.9M141.79M

Corcept Therapeutics Incorporated

NASDAQ:CORT

Intrinsic Alpha fair value

Locked

Current Price

$67.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.